Avid Bioservices Inc (CDMO)

[Protector]

bio, converts again the broad spectrum of PS-targetting of which we hold the IP.

In the beginning interferon replacement(s) were mentioned but not taken serous. The same with the early mention of Bavi's possible use in Alzheimer as a way to get to the brain and pass the brain-blood barrier (I think Roche even has a video out showing what role PS plays there).

Today Bavituximab or at least PPHM IP related to PS-Targeting is all over the place.

- Oncology
--> Chemo+Bavi
--> Radio+Bavi
--> anti-XYZ+Bavi (onco-immunology)
- Viral
- Inflamations/Infections
- Digital Imaging
- Vacines
- Interferon replacements
- etc

These are 6 world markets of UNSEEN YEARLY VALUE. If PPHM can only make it in two of them then even today's biggest BP may soon look like a lap-dog. I know, for the moment we trade 1.40$ :) and for sure that must mean all the above is not true :)